Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity
Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity
复制标题
以低疾病活动度为目标考虑年轻发病和老年发病类风湿性关节炎用药差异
DOI：
10.1080/14397595.2021.1883251
复制
发表时间：
2021
影响因子：
2.2
通讯作者：
Imai Shinji
中科院分区：
文献类型：
--
作者：
Kumagai Kosuke;Okumura Noriaki;Amano Yasutaka;Yayama Takafumi;Mimura Tomohiro;Maeda Tsutomu;Kubo Mitsuhiko;Mori Kanji;Barrett-Jolley Richard;Imai Shinji
据报道，老年性类风湿性关节炎(EORA)与年轻发病的类风湿性关节炎(YORA)在患者背景和药物治疗方面存在差异。方法比较EORA(n= 70)和YORA(n= 190)患者的人口学特征、临床病史和治疗方法。结果两组患者的平均年龄(73.8vs.57.8岁)、病程(6.66vs.14.7年)和性别(62.9%男性vs.83.7%)有显著差异，但类风湿因子阳性率(85.3%vs.80.7%)，Eora组和YORA组的抗瓜氨酸肽抗体阳性率(86.5%比87.7%)、简化疾病活动指数(4.28比4.59)或疾病活动评分28-CRP(1.99比2.04)。强的松龙使用率(37.1%比36.3%)、甲氨蝶呤用量(1.45vs.1.41 mg)和甲氨蝶呤使用量(55.7%vs.65.3%)也没有显著差异。然而，EORA患者的甲氨蝶呤剂量(2.89vs.4.09 mg/周，p= .011)和生物制剂的总使用量(32.9%vs.56.3%，p= .0012)显著低于YORA患者。
ObjectivesElderly-onset rheumatoid arthritis (EORA) is reported to differ from young-onset rheumatoid arthritis (YORA) with regard to patient background and drug treatment. We examined the amount of drug administered to patients who achieved low disease activity (LDA) for rheumatoid arthritis at our hospital.MethodsDemographics, clinical history, and treatments were compared between patients with EORA (n= 70) and YORA (n= 190).ResultsThere was a significant difference in the average age (73.8 vs. 57.8 years), disease duration (6.66 vs. 14.7 years), and sex (62.9% males vs. 83.7% females), but no difference in rheumatoid factor positivity (85.3% vs. 80.7%), anti-citrullinated peptide antibody positivity (86.5% vs. 87.7%), simplified disease activity index (4.28 vs. 4.59), or disease activity score 28-CRP (1.99 vs. 2.04) in the EORA and YORA groups, respectively. There were also no significant differences in prednisolone use (37.1% vs. 36.3%), amount of methotrexate administered (MTX) (1.45 vs. 1.41 mg), and MTX use (55.7% vs. 65.3%). However, the MTX dose (2.89 vs. 4.09 mg/week,p= .011) and overall biologics use (32.9% vs. 56.3%,p= .0012) were significantly lower in patients with EORA than in those with YORA.ConclusionPatients with EORA may be able to achieve LDA with lower drug dosage than those with YORA.